The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing

Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acut...

Full description

Bibliographic Details

Published in:	Cells
Main Authors:	Hazel Dunbar, Daniel J Weiss, Sara Rolandsson Enes, John G Laffey, Karen English
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Subjects:	MSC licensing lung microenvironment inflammatory cytokines
Online Access:	https://www.mdpi.com/2073-4409/10/11/2982